SK3202001A3 - Drug and a pharmaceutical composition for treating diabetes, insulin resistance, obesity, hyperglycemia, hyperinsulinemia or increased level - Google Patents

Drug and a pharmaceutical composition for treating diabetes, insulin resistance, obesity, hyperglycemia, hyperinsulinemia or increased level Download PDF

Info

Publication number: SK3202001A3
Authority: SK; Slovakia
Prior art keywords: alkyl; inhibitor; derivative; phenyl; hydrogen
Prior art date: 1998-09-17

Application number

SK320-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Jeffrey A Robl

Rex A Parker

Scott A Biller

Haris Jamil

Bruce L Jacobson

Krishna Kodukula

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-17

Filing date

1999-09-13

Publication date

2002-04-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22280975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK3202001(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-13 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2002-04-04 Publication of SK3202001A3 publication Critical patent/SK3202001A3/sk

Links

208000001072 type 2 diabetes mellitus Diseases 0.000 title claims description 29
208000008589 Obesity Diseases 0.000 title claims description 24
235000020824 obesity Nutrition 0.000 title claims description 24
206010022489 Insulin Resistance Diseases 0.000 title claims description 23
239000003814 drug Substances 0.000 title claims description 22
206010012601 diabetes mellitus Diseases 0.000 title claims description 20
201000001421 hyperglycemia Diseases 0.000 title claims description 20
206010060378 Hyperinsulinaemia Diseases 0.000 title claims description 18
230000003451 hyperinsulinaemic effect Effects 0.000 title claims description 18
201000008980 hyperinsulinism Diseases 0.000 title claims description 18
229940079593 drug Drugs 0.000 title description 5
239000008194 pharmaceutical composition Substances 0.000 title description 4
101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 claims abstract description 113
102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 claims abstract description 100
239000003112 inhibitor Substances 0.000 claims abstract description 81
-1 alkyl radical Chemical class 0.000 claims description 89
125000000217 alkyl group Chemical group 0.000 claims description 72
229910052739 hydrogen Inorganic materials 0.000 claims description 72
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 54
150000001875 compounds Chemical class 0.000 claims description 54
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
239000001257 hydrogen Substances 0.000 claims description 42
229910052736 halogen Inorganic materials 0.000 claims description 35
125000003118 aryl group Chemical group 0.000 claims description 34
150000002367 halogens Chemical class 0.000 claims description 31
229910052799 carbon Inorganic materials 0.000 claims description 30
150000003839 salts Chemical class 0.000 claims description 28
239000003472 antidiabetic agent Substances 0.000 claims description 23
235000014113 dietary fatty acids Nutrition 0.000 claims description 23
229930195729 fatty acid Natural products 0.000 claims description 23
239000000194 fatty acid Substances 0.000 claims description 23
150000004665 fatty acids Chemical class 0.000 claims description 23
125000001424 substituent group Chemical group 0.000 claims description 21
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 19
208000006575 hypertriglyceridemia Diseases 0.000 claims description 17
238000004519 manufacturing process Methods 0.000 claims description 17
235000011187 glycerol Nutrition 0.000 claims description 16
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 16
229910052717 sulfur Inorganic materials 0.000 claims description 16
229940125708 antidiabetic agent Drugs 0.000 claims description 15
125000001072 heteroaryl group Chemical group 0.000 claims description 15
125000004093 cyano group Chemical group *C#N 0.000 claims description 14
125000000623 heterocyclic group Chemical group 0.000 claims description 14
229910052760 oxygen Inorganic materials 0.000 claims description 14
125000003545 alkoxy group Chemical group 0.000 claims description 13
102000047030 human FABP4 Human genes 0.000 claims description 13
150000002431 hydrogen Chemical class 0.000 claims description 13
125000004432 carbon atom Chemical group C* 0.000 claims description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
229910052757 nitrogen Inorganic materials 0.000 claims description 12
125000003710 aryl alkyl group Chemical group 0.000 claims description 11
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
239000001301 oxygen Substances 0.000 claims description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
125000000539 amino acid group Chemical group 0.000 claims description 10
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
229920006395 saturated elastomer Polymers 0.000 claims description 10
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
239000002253 acid Substances 0.000 claims description 9
239000011593 sulfur Substances 0.000 claims description 9
102000004877 Insulin Human genes 0.000 claims description 8
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
150000002148 esters Chemical class 0.000 claims description 8
229940125396 insulin Drugs 0.000 claims description 8
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 7
AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 claims description 7
108090001061 Insulin Proteins 0.000 claims description 7
229940123464 Thiazolidinedione Drugs 0.000 claims description 7
229910052783 alkali metal Inorganic materials 0.000 claims description 7
125000004414 alkyl thio group Chemical group 0.000 claims description 7
230000027455 binding Effects 0.000 claims description 7
229910052801 chlorine Inorganic materials 0.000 claims description 7
150000003230 pyrimidines Chemical class 0.000 claims description 7
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 6
229960004580 glibenclamide Drugs 0.000 claims description 6
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 6
125000005843 halogen group Chemical group 0.000 claims description 6
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
230000003993 interaction Effects 0.000 claims description 6
125000005647 linker group Chemical group 0.000 claims description 6
125000004193 piperazinyl group Chemical group 0.000 claims description 6
229940002612 prodrug Drugs 0.000 claims description 6
239000000651 prodrug Substances 0.000 claims description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 5
229940123208 Biguanide Drugs 0.000 claims description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
102000004366 Glucosidases Human genes 0.000 claims description 5
108010056771 Glucosidases Proteins 0.000 claims description 5
229940124754 PPAR-alpha/gamma agonist Drugs 0.000 claims description 5
229910052794 bromium Inorganic materials 0.000 claims description 5
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
230000009977 dual effect Effects 0.000 claims description 5
229910052731 fluorine Inorganic materials 0.000 claims description 5
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 5
229960003105 metformin Drugs 0.000 claims description 5
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 5
SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 4
229940122355 Insulin sensitizer Drugs 0.000 claims description 4
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 4
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
125000002947 alkylene group Chemical group 0.000 claims description 4
125000002102 aryl alkyloxo group Chemical group 0.000 claims description 4
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
229910002091 carbon monoxide Inorganic materials 0.000 claims description 4
235000021588 free fatty acids Nutrition 0.000 claims description 4
229950004994 meglitinide Drugs 0.000 claims description 4
150000007978 oxazole derivatives Chemical class 0.000 claims description 4
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
239000012453 solvate Substances 0.000 claims description 4
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 4
229960001641 troglitazone Drugs 0.000 claims description 4
125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 3
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
CQHYICHMGNSGQH-UHFFFAOYSA-N 1,3-oxazole-2-carboxylic acid Chemical class OC(=O)C1=NC=CO1 CQHYICHMGNSGQH-UHFFFAOYSA-N 0.000 claims description 3
BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 3
OSCOEGOIEGAFDI-UHFFFAOYSA-N 2-(1,3-oxazol-2-yl)-4-phenyl-1,3-oxazole Chemical class C1=COC(C=2OC=C(N=2)C=2C=CC=CC=2)=N1 OSCOEGOIEGAFDI-UHFFFAOYSA-N 0.000 claims description 3
ODKHOKLXMBWVOQ-UHFFFAOYSA-N 4,5-diphenyl-1,3-oxazole Chemical class O1C=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 ODKHOKLXMBWVOQ-UHFFFAOYSA-N 0.000 claims description 3
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 3
FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 3
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 3
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
229960001761 chlorpropamide Drugs 0.000 claims description 3
229960000346 gliclazide Drugs 0.000 claims description 3
229960004346 glimepiride Drugs 0.000 claims description 3
WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 3
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 3
229960001381 glipizide Drugs 0.000 claims description 3
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 3
125000001544 thienyl group Chemical group 0.000 claims description 3
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 3
XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 2
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 2
QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 claims description 2
125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 2
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims description 2
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims description 2
FTPLHCPJZLDACP-UHFFFAOYSA-N 5,6-dihydrofuro[2,3-d]pyrimidine Chemical compound N1=CN=C2OCCC2=C1 FTPLHCPJZLDACP-UHFFFAOYSA-N 0.000 claims description 2
NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 claims description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 2
JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 claims description 2
IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims description 2
150000001204 N-oxides Chemical class 0.000 claims description 2
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
229960002632 acarbose Drugs 0.000 claims description 2
XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 2
230000002378 acidificating effect Effects 0.000 claims description 2
150000007513 acids Chemical class 0.000 claims description 2
150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
150000001336 alkenes Chemical class 0.000 claims description 2
150000007980 azole derivatives Chemical class 0.000 claims description 2
125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 2
125000004534 benzothien-2-yl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
150000004283 biguanides Chemical group 0.000 claims description 2
230000036765 blood level Effects 0.000 claims description 2
150000004677 hydrates Chemical class 0.000 claims description 2
ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 2
229960001110 miglitol Drugs 0.000 claims description 2
125000006574 non-aromatic ring group Chemical group 0.000 claims description 2
125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
229910052698 phosphorus Inorganic materials 0.000 claims description 2
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 2
CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 claims description 2
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 2
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 2
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 2
QGDYVSSVBYMOJN-UHFFFAOYSA-N pyrimido[4,5-d]pyrimidine Chemical compound C1=NC=NC2=NC=NC=C21 QGDYVSSVBYMOJN-UHFFFAOYSA-N 0.000 claims description 2
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 2
125000004262 quinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 claims description 2
229960002354 repaglinide Drugs 0.000 claims description 2
125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 claims description 2
DDWBRNXDKNIQDY-UHFFFAOYSA-N thieno[2,3-d]pyrimidine Chemical compound N1=CN=C2SC=CC2=C1 DDWBRNXDKNIQDY-UHFFFAOYSA-N 0.000 claims description 2
229930192474 thiophene Natural products 0.000 claims description 2
IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
229960005150 glycerol Drugs 0.000 claims 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 3
YIDGOFMCVVAHPY-UHFFFAOYSA-N 2-phenylmethoxypyrimidine Chemical class C=1C=CC=CC=1COC1=NC=CC=N1 YIDGOFMCVVAHPY-UHFFFAOYSA-N 0.000 claims 2
125000004043 oxo group Chemical group O=* 0.000 claims 2
XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims 1
BCOUPMDJZSBCCR-UHFFFAOYSA-N 2-(naphthalen-1-ylmethoxy)pyrimidine Chemical class C=1C=CC2=CC=CC=C2C=1COC1=NC=CC=N1 BCOUPMDJZSBCCR-UHFFFAOYSA-N 0.000 claims 1
BCCIPSPVTGITDC-UHFFFAOYSA-N 5,6-dihydrothieno[2,3-d]pyrimidine Chemical compound N1=CN=C2SCCC2=C1 BCCIPSPVTGITDC-UHFFFAOYSA-N 0.000 claims 1
TYMQPXWYXSQYDE-UHFFFAOYSA-N N1=CN=CC2=C1OC=C2.N2=CN=CC1=C2NCC1 Chemical compound N1=CN=CC2=C1OC=C2.N2=CN=CC1=C2NCC1 TYMQPXWYXSQYDE-UHFFFAOYSA-N 0.000 claims 1
JNRGNBBXGZMDOO-UHFFFAOYSA-N acetic acid;1h-pyridazin-6-one Chemical group CC(O)=O.O=C1C=CC=NN1 JNRGNBBXGZMDOO-UHFFFAOYSA-N 0.000 claims 1
125000005133 alkynyloxy group Chemical group 0.000 claims 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
125000003386 piperidinyl group Chemical group 0.000 claims 1
UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 claims 1
238000000034 method Methods 0.000 abstract description 17
239000003795 chemical substances by application Substances 0.000 abstract description 2
201000010099 disease Diseases 0.000 abstract description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
201000001320 Atherosclerosis Diseases 0.000 abstract 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
230000000879 anti-atherosclerotic effect Effects 0.000 abstract 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
229960002965 pravastatin Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 description 12
125000004446 heteroarylalkyl group Chemical group 0.000 description 12
238000003556 assay Methods 0.000 description 10
125000000753 cycloalkyl group Chemical group 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
102000030914 Fatty Acid-Binding Human genes 0.000 description 6
229940100389 Sulfonylurea Drugs 0.000 description 6
125000004448 alkyl carbonyl group Chemical group 0.000 description 6
108091022862 fatty acid binding Proteins 0.000 description 6
125000005842 heteroatom Chemical group 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
239000000203 mixture Substances 0.000 description 5
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 4
239000013078 crystal Substances 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000000746 purification Methods 0.000 description 4
FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 3
XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 3
210000001789 adipocyte Anatomy 0.000 description 3
229940127003 anti-diabetic drug Drugs 0.000 description 3
230000002058 anti-hyperglycaemic effect Effects 0.000 description 3
125000004104 aryloxy group Chemical group 0.000 description 3
239000002775 capsule Substances 0.000 description 3
125000001188 haloalkyl group Chemical group 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000003538 oral antidiabetic agent Substances 0.000 description 3
239000006186 oral dosage form Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
210000000577 adipose tissue Anatomy 0.000 description 2
125000003342 alkenyl group Chemical group 0.000 description 2
150000005215 alkyl ethers Chemical class 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000003178 anti-diabetic effect Effects 0.000 description 2
125000004658 aryl carbonyl amino group Chemical group 0.000 description 2
125000005110 aryl thio group Chemical group 0.000 description 2
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
125000005553 heteroaryloxy group Chemical group 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
125000001041 indolyl group Chemical group 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
125000002971 oxazolyl group Chemical group 0.000 description 2
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
239000008057 potassium phosphate buffer Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 2
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
ZOMUCVSKCXNYGL-UHFFFAOYSA-N (4,5-diphenyl-1,3-oxazol-2-yl)sulfanylformic acid Chemical class O1C(SC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 ZOMUCVSKCXNYGL-UHFFFAOYSA-N 0.000 description 1
125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 1
125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
YHPJVEVBHRHVGO-UHFFFAOYSA-N 1-anilinonaphthalene-2-sulfonic acid Chemical compound OS(=O)(=O)C1=CC=C2C=CC=CC2=C1NC1=CC=CC=C1 YHPJVEVBHRHVGO-UHFFFAOYSA-N 0.000 description 1
QIJIUJYANDSEKG-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-amine Chemical compound CC(C)(C)CC(C)(C)N QIJIUJYANDSEKG-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 1
BQRBAXFOPZRMCU-UHFFFAOYSA-N 5-chloro-1h-imidazole Chemical compound ClC1=CN=CN1 BQRBAXFOPZRMCU-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
QMQZYILAWUOLPV-JYJNAYRXSA-N Arg-Tyr-Arg Chemical group NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CC1=CC=C(O)C=C1 QMQZYILAWUOLPV-JYJNAYRXSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000672609 Escherichia coli BL21 Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
101710092928 Insulin-like peptide-1 Proteins 0.000 description 1
125000000773 L-serino group Chemical group [H]OC(=O)[C@@]([H])(N([H])*)C([H])([H])O[H] 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
101000940758 Mus musculus Cysteine and glycine-rich protein 2 Proteins 0.000 description 1
101001087410 Mus musculus Tyrosine-protein phosphatase non-receptor type 18 Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
101000872072 Ornithorhynchus anatinus Defensin-like peptide 1 Proteins 0.000 description 1
229910018830 PO3H Inorganic materials 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241001275117 Seres Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
125000005135 aryl sulfinyl group Chemical group 0.000 description 1
125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
125000005164 aryl thioalkyl group Chemical group 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
150000008366 benzophenones Chemical class 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
238000005460 biophysical method Methods 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
238000002447 crystallographic data Methods 0.000 description 1
125000005112 cycloalkylalkoxy group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
229950006689 darglitazone Drugs 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229950002375 englitazone Drugs 0.000 description 1
125000002587 enol group Chemical group 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000004129 fatty acid metabolism Effects 0.000 description 1
230000004907 flux Effects 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000000446 fuel Substances 0.000 description 1
KQGXYVJZOMKLSA-UHFFFAOYSA-N furo[2,3-d]pyrimidine Chemical compound N1=CN=C2OC=CC2=C1 KQGXYVJZOMKLSA-UHFFFAOYSA-N 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000004438 haloalkoxy group Chemical group 0.000 description 1
238000012835 hanging drop method Methods 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
125000005368 heteroarylthio group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
235000009200 high fat diet Nutrition 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
230000035772 mutation Effects 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
150000002829 nitrogen Chemical class 0.000 description 1
229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
229960003243 phenformin Drugs 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
229960005095 pioglitazone Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
229940096058 prandin Drugs 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
230000009627 regulation of fatty acid transport Effects 0.000 description 1
229960004586 rosiglitazone Drugs 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
229940110862 starlix Drugs 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
239000003826 tablet Substances 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000007704 transition Effects 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
125000004385 trihaloalkyl group Chemical group 0.000 description 1
125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000003041 virtual screening Methods 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Obesity (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Steroid Compounds (AREA)
Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
Plural Heterocyclic Compounds (AREA)

SK320-2001A 1998-09-17 1999-09-13 Drug and a pharmaceutical composition for treating diabetes, insulin resistance, obesity, hyperglycemia, hyperinsulinemia or increased level SK3202001A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10067798P	1998-09-17	1998-09-17
PCT/US1999/020946 WO2000015229A1 (en)	1998-09-17	1999-09-13	METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION

Publications (1)

Publication Number	Publication Date
SK3202001A3 true SK3202001A3 (en)	2002-04-04

Family

ID=22280975

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK320-2001A SK3202001A3 (en)	1998-09-17	1999-09-13	Drug and a pharmaceutical composition for treating diabetes, insulin resistance, obesity, hyperglycemia, hyperinsulinemia or increased level

Country Status (30)

Country	Link
US (1)	US20020035064A1 (et)
EP (2)	EP1121129B1 (et)
JP (2)	JP2002524517A (et)
KR (2)	KR20010079842A (et)
CN (2)	CN1319012A (et)
AT (1)	ATE406898T1 (et)
AU (2)	AU754488B2 (et)
BG (2)	BG105432A (et)
BR (2)	BR9913831A (et)
CA (2)	CA2344300A1 (et)
CO (2)	CO5130026A1 (et)
CZ (2)	CZ2001965A3 (et)
DE (1)	DE69939481D1 (et)
EE (2)	EE200100155A (et)
ES (1)	ES2311306T3 (et)
GE (2)	GEP20033045B (et)
HU (2)	HUP0104108A2 (et)
ID (2)	ID28450A (et)
IL (2)	IL141785A0 (et)
LT (2)	LT4871B (et)
LV (2)	LV12686B (et)
NO (2)	NO20011352L (et)
NZ (2)	NZ510209A (et)
PE (2)	PE20001056A1 (et)
PL (2)	PL346660A1 (et)
SK (1)	SK3202001A3 (et)
TR (2)	TR200100774T2 (et)
UY (2)	UY25713A1 (et)
WO (2)	WO2000015230A1 (et)
ZA (2)	ZA200207433B (et)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2311125C (en) *	1997-11-19	2011-01-18	Takeda Chemical Industries, Ltd.	Apoptosis inhibitor
AU2005201289B2 (en) *	1999-02-12	2008-04-17	President And Fellows Of Harvard College	Inhibiting formation of atherosclerotic lesions
JP2002536459A (ja) *	1999-02-12	2002-10-29	プレジデントアンドフェローズオブハーヴァードカレッジ	アテローム性動脈硬化症性病変の形成の阻害
US6548529B1 (en)	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
US6586438B2 (en)	1999-11-03	2003-07-01	Bristol-Myers Squibb Co.	Antidiabetic formulation and method
EP1253925A1 (en)	2000-01-28	2002-11-06	Bristol-Myers Squibb Company	Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
HUP0500543A2 (hu) *	2000-11-20	2005-09-28	Bristol-Myers Squibb Company	Piridonszármazékok mint aP2 inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
EP1385549A2 (en) *	2001-03-12	2004-02-04	Novartis AG	Combination of nateglinide or repaglinide with at least one further antidiabetic compound
US6919323B2 (en)	2001-07-13	2005-07-19	Bristol-Myers Squibb Company	Pyridazinone inhibitors of fatty acid binding protein and method
AU2002322585A1 (en) *	2001-07-20	2003-03-03	Adipogenix, Inc.	Fat accumulation-modulating compounds
WO2003043624A1 (en)	2001-11-16	2003-05-30	Bristol-Myers Squibb Company	Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US7572922B2 (en)	2003-01-27	2009-08-11	Merck & Co., Inc.	Substituted pyrazoles, compositions containing such compounds and methods of use
AU2004224825A1 (en) *	2003-03-26	2004-10-07	Crc For Asthma Limited	Therapeutic and prophylactic compositions and uses therefor
WO2004096977A2 (en) *	2003-04-30	2004-11-11	Pfizer Products Inc.	Crystal structure of homo sapiens adipocyte lipid binding protein and uses thereof
NZ549721A (en)	2004-03-05	2010-08-27	Univ Pennsylvania	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
CN1964947A (zh)	2004-06-04	2007-05-16	默克公司	吡唑衍生物、包含其的组合物及其用法
WO2006028970A1 (en)	2004-09-02	2006-03-16	Cengent Therapeutics, Inc.	Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
SG164378A1 (en)	2005-02-17	2010-09-29	Synta Pharmaceuticals Corp	Compounds for the treatment of proliferative disorders
WO2007015999A2 (en)	2005-07-26	2007-02-08	Merck & Co., Inc.	Process for synthesizing a substituted pyrazole
JP2009511635A (ja) *	2005-10-18	2009-03-19	エージェリオンファーマシューティカルズ	哺乳動物における高脂血症に関連する障害を治療するための方法
EP2037929A4 (en) *	2006-06-02	2010-02-17	Univ San Diego State Res Found	COMPOSITIONS AND METHODS FOR REDUCING HYPERLIPIDEMIA
US20080161279A1 (en) *	2006-12-21	2008-07-03	Wisler Gerald L	Methods of Treating Obesity
US8815875B2 (en) *	2008-11-12	2014-08-26	Merck Sharp & Dohme Corp.	Inhibitors of fatty acid binding protein (FABP)
CN107141353A (zh) *	2009-03-05	2017-09-08	哈佛学院董事会	分泌的aP2及其抑制方法
JP6514282B2 (ja) *	2014-03-24	2019-05-15	花王株式会社	Ｇｉｐ上昇抑制剤の評価又は選択方法
JP6223376B2 (ja) *	2014-03-24	2017-11-01	花王株式会社	Ｇｉｐ上昇抑制剤の評価又は選択方法
EP3288584A2 (en)	2015-04-30	2018-03-07	President and Fellows of Harvard College	Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
EA201990136A1 (ru) *	2016-06-27	2019-05-31	Президент Энд Феллоуз Оф Гарвард Колледж	Соединения, применимые для лечения нарушений обмена веществ
CA3066733A1 (en)	2017-06-09	2018-12-13	President And Fellows Of Harvard College	Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
EP4171736A4 (en)	2020-06-27	2024-07-03	Crescenta Biosciences	NEW CELL METABOLISM MODULATING COMPOUNDS AND THEIR USES
EP4188372A1 (en)	2020-07-29	2023-06-07	Amryt Pharmaceuticals Inc.	Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
US12138243B2 (en)	2021-12-31	2024-11-12	Crescenta Biosciences	Antiviral use of FABP4 modulating compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2129012A1 (de)	1971-06-11	1973-01-04	Merck Patent Gmbh	Azol-derivate
FR2156486A1 (en)	1971-10-22	1973-06-01	Roussel Uclaf	Oxazolyl oxy or thio acetic acids - analgesics antipyretics and anti-inflammatories
JPS5612114B2 (et)	1974-06-07	1981-03-18
GB1507032A (en)	1974-08-06	1978-04-12	Serono Lab	2-thiol-4,5-diphenyloxazole s-derivatives
NO154918C (no)	1977-08-27	1987-01-14	Bayer Ag	Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en)	1979-06-15	1980-11-04	Merck & Co., Inc.	Hypocholesteremic fermentation products and process of preparation
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
CA1327360C (en)	1983-11-14	1994-03-01	William F. Hoffman	Oxo-analogs of mevinolin-like antihypercholesterolemic agents
DE3543999A1 (de)	1985-12-13	1987-06-19	Bayer Ag	Hochreine acarbose
DK277488A (da)	1987-05-22	1988-11-23	Squibb & Sons Inc	Phosporholdige hmg-coa-reduktaseinhibitorer, deres anvendelse og fremstilling samt mellemprodukter ved fremstillingen
FR2647676A1 (fr)	1989-06-05	1990-12-07	Union Pharma Scient Appl	Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
US5218124A (en) *	1989-10-27	1993-06-08	American Home Products Corporation	Substituted benzoylbenzene-, biphenyl- and 2-oxazole-alkanoic acid derivatives as inhibitors of pla2 and lipoxygenase
PT95690A (pt) *	1989-10-27	1991-09-13	American Home Prod	Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase
US5262540A (en) *	1989-12-20	1993-11-16	Bristol-Myers Squibb Company	[2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters
FR2663331B1 (fr)	1990-06-14	1994-05-06	Bellon Laboratoires	Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
GB9019841D0 (en) *	1990-09-11	1990-10-24	Smith Kline French Lab	Compounds
US5254576A (en) *	1992-04-03	1993-10-19	Bristol-Myers Squibb Company	Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
US5348969A (en) *	1992-04-03	1994-09-20	Bristol-Myers Squibb Company	Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5187188A (en) *	1992-04-03	1993-02-16	Bristol-Myers Squibb Company	Oxazole carboxylic acid derivatives
US5594016A (en)	1992-12-28	1997-01-14	Mitsubishi Chemical Corporation	Naphthalene derivatives
US5346701A (en)	1993-02-22	1994-09-13	Theratech, Inc.	Transmucosal delivery of macromolecular drugs
US5362879A (en) *	1993-04-15	1994-11-08	Bristol-Myers Squibb Company	4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
US5739135A (en)	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
DE4340781C3 (de)	1993-11-30	2000-01-27	Novartis Ag	Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
JPH09506894A (ja) *	1993-12-20	1997-07-08	藤沢薬品工業株式会社	４，５−ジアリールオキサゾール誘導体
US5599770A (en)	1994-07-15	1997-02-04	Kureha Kagaku Kogyo Kabushiki Kaisha	Herbicidal composition containing 2-benzyloxypyrimidine derivatives, processes for producing the derivatives and 2-benzyloxypyrimidine derivatives
BR9508468A (pt)	1994-07-29	1997-11-25	Smithkline Beecham Plc	Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
US5612359A (en) *	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
UA56992C2 (uk)	1995-05-08	2003-06-16	Фармація Енд Апджон Компані	<font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5620997A (en)	1995-05-31	1997-04-15	Warner-Lambert Company	Isothiazolones
JP3144624B2 (ja)	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
WO1997012613A1 (en)	1995-10-05	1997-04-10	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
GB9600231D0 (en)	1996-01-05	1996-03-06	Foster Wheeler Petrol Dev Ltd	Spacing bouy for flexible risers
AUPO134596A0 (en)	1996-08-01	1996-08-22	Jal Pastoral Co. Pty Ltd	Demountable article carrier for motor vehicles
US5760246A (en)	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

1999
- 1999-09-13 CA CA002344300A patent/CA2344300A1/en not_active Abandoned
- 1999-09-13 BR BR9913831-0A patent/BR9913831A/pt not_active IP Right Cessation
- 1999-09-13 IL IL14178599A patent/IL141785A0/xx unknown
- 1999-09-13 KR KR1020017003408A patent/KR20010079842A/ko not_active Withdrawn
- 1999-09-13 WO PCT/US1999/021069 patent/WO2000015230A1/en not_active Ceased
- 1999-09-13 TR TR2001/00774T patent/TR200100774T2/xx unknown
- 1999-09-13 NZ NZ510209A patent/NZ510209A/en unknown
- 1999-09-13 ID IDW20010624A patent/ID28450A/id unknown
- 1999-09-13 AU AU63877/99A patent/AU754488B2/en not_active Ceased
- 1999-09-13 PL PL99346660A patent/PL346660A1/xx not_active Application Discontinuation
- 1999-09-13 JP JP2000569813A patent/JP2002524517A/ja active Pending
- 1999-09-13 EE EEP200100155A patent/EE200100155A/et unknown
- 1999-09-13 HU HU0104108A patent/HUP0104108A2/hu unknown
- 1999-09-13 AU AU61437/99A patent/AU755563B2/en not_active Ceased
- 1999-09-13 EP EP99951438A patent/EP1121129B1/en not_active Revoked
- 1999-09-13 EE EEP200100154A patent/EE04356B1/et not_active IP Right Cessation
- 1999-09-13 HU HU0104240A patent/HUP0104240A2/hu unknown
- 1999-09-13 CN CN99811096A patent/CN1319012A/zh active Pending
- 1999-09-13 AT AT99951438T patent/ATE406898T1/de not_active IP Right Cessation
- 1999-09-13 DE DE69939481T patent/DE69939481D1/de not_active Revoked
- 1999-09-13 TR TR2001/00773T patent/TR200100773T2/xx unknown
- 1999-09-13 GE GEAP19995860A patent/GEP20033045B/en unknown
- 1999-09-13 KR KR1020017003411A patent/KR20010075150A/ko not_active Withdrawn
- 1999-09-13 SK SK320-2001A patent/SK3202001A3/sk unknown
- 1999-09-13 CN CN99811000A patent/CN1317970A/zh active Pending
- 1999-09-13 ID IDW20010626A patent/ID27833A/id unknown
- 1999-09-13 CZ CZ2001965A patent/CZ2001965A3/cs unknown
- 1999-09-13 CA CA002344309A patent/CA2344309A1/en not_active Abandoned
- 1999-09-13 CZ CZ2001964A patent/CZ2001964A3/cs unknown
- 1999-09-13 EP EP99948210A patent/EP1113801A4/en not_active Withdrawn
- 1999-09-13 ES ES99951438T patent/ES2311306T3/es not_active Expired - Lifetime
- 1999-09-13 GE GEAP19995861A patent/GEP20033044B/en unknown
- 1999-09-13 BR BR9913833-6A patent/BR9913833A/pt not_active IP Right Cessation
- 1999-09-13 IL IL14178699A patent/IL141786A0/xx unknown
- 1999-09-13 WO PCT/US1999/020946 patent/WO2000015229A1/en not_active Ceased
- 1999-09-13 JP JP2000569814A patent/JP2002524518A/ja active Pending
- 1999-09-13 PL PL99346661A patent/PL346661A1/xx unknown
- 1999-09-13 NZ NZ510207A patent/NZ510207A/en unknown
- 1999-09-15 CO CO99058376A patent/CO5130026A1/es unknown
- 1999-09-15 CO CO99058374A patent/CO5130025A1/es unknown
- 1999-09-16 UY UY25713A patent/UY25713A1/es unknown
- 1999-09-16 UY UY25714A patent/UY25714A1/es unknown
- 1999-09-17 PE PE1999000943A patent/PE20001056A1/es not_active Application Discontinuation
- 1999-09-17 PE PE1999000944A patent/PE20001047A1/es not_active Application Discontinuation
2001
- 2001-03-16 LT LT2001022A patent/LT4871B/lt not_active IP Right Cessation
- 2001-03-16 LT LT2001023A patent/LT4870B/lt not_active IP Right Cessation
- 2001-03-16 NO NO20011352A patent/NO20011352L/no not_active Application Discontinuation
- 2001-03-16 NO NO20011351A patent/NO20011351L/no unknown
- 2001-04-10 BG BG105432A patent/BG105432A/xx unknown
- 2001-04-10 BG BG105431A patent/BG105431A/xx unknown
- 2001-04-12 LV LV010057A patent/LV12686B/xx unknown
- 2001-04-12 LV LV010058A patent/LV12687B/xx unknown
- 2001-07-13 US US09/905,235 patent/US20020035064A1/en not_active Abandoned
2002
- 2002-09-16 ZA ZA200207433A patent/ZA200207433B/en unknown
- 2002-09-16 ZA ZA200207430A patent/ZA200207430B/en unknown

Also Published As

Publication number	Publication date
HUP0104108A2 (hu)	2002-03-28
UY25714A1 (es)	2001-08-27
US20020035064A1 (en)	2002-03-21
IL141786A0 (en)	2002-03-10
NO20011352D0 (no)	2001-03-16
EE200100155A (et)	2002-08-15
HUP0104240A2 (hu)	2002-03-28
AU6143799A (en)	2000-04-03
LT4871B (lt)	2001-12-27
LV12686B (lv)	2001-10-20
PE20001047A1 (es)	2000-12-24
NO20011351L (no)	2001-05-11
EE04356B1 (et)	2004-10-15
CA2344300A1 (en)	2000-03-23
ID28450A (id)	2001-05-24
EP1121129B1 (en)	2008-09-03
EP1121129A4 (en)	2002-10-16
EP1113801A4 (en)	2002-10-02
ES2311306T3 (es)	2009-02-01
EP1113801A1 (en)	2001-07-11
CN1317970A (zh)	2001-10-17
LV12687A (en)	2001-07-20
JP2002524518A (ja)	2002-08-06
KR20010079842A (ko)	2001-08-22
GEP20033044B (en)	2003-08-25
IL141785A0 (en)	2002-03-10
AU6387799A (en)	2000-04-03
WO2000015230A1 (en)	2000-03-23
NZ510209A (en)	2003-07-25
BR9913831A (pt)	2001-05-29
LV12686A (en)	2001-07-20
BR9913833A (pt)	2001-05-29
BG105431A (en)	2001-12-29
CA2344309A1 (en)	2000-03-23
TR200100773T2 (tr)	2001-07-23
EP1121129A1 (en)	2001-08-08
CZ2001965A3 (cs)	2002-02-13
CZ2001964A3 (cs)	2002-01-16
LT2001023A (en)	2001-08-27
PE20001056A1 (es)	2000-12-24
NO20011351D0 (no)	2001-03-16
DE69939481D1 (de)	2008-10-16
TR200100774T2 (tr)	2001-12-21
LT2001022A (en)	2001-08-27
NZ510207A (en)	2003-08-29
UY25713A1 (es)	2001-08-27
PL346661A1 (en)	2002-02-25
WO2000015229A1 (en)	2000-03-23
LV12687B (lv)	2001-10-20
CN1319012A (zh)	2001-10-24
AU755563B2 (en)	2002-12-12
AU754488B2 (en)	2002-11-14
GEP20033045B (en)	2003-08-25
JP2002524517A (ja)	2002-08-06
EE200100154A (et)	2002-12-16
CO5130025A1 (es)	2002-02-27
PL346660A1 (en)	2002-02-25
ZA200207433B (en)	2003-10-27
ID27833A (id)	2001-04-26
KR20010075150A (ko)	2001-08-09
LT4870B (lt)	2001-12-27
NO20011352L (no)	2001-05-11
ATE406898T1 (de)	2008-09-15
CO5130026A1 (es)	2002-02-27
BG105432A (en)	2001-12-29
ZA200207430B (en)	2003-09-16

Publication	Publication Date	Title
EP1121129B1 (en)	2008-09-03	METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS
KR101345316B1 (ko)	2013-12-27	당뇨병 치료용 디펩티딜 펩티다아제 억제제
US20090143469A1 (en)	2009-06-04	Salts of nateglinide
CN1400908A (zh)	2003-03-05	含有二肽基肽酶－iv抑制剂的联合形式
US20140228286A1 (en)	2014-08-14	Specific pde4b-inhibitors for the treatment of diabetes mellitus
US20090076033A1 (en)	2009-03-19	Method for treating atherosclerosis employing an aP2 inhibitor and combination
KR20150038706A (ko)	2015-04-08	디펩티딜 펩티다아제 억제제의 주1회 투여
US7390824B1 (en)	2008-06-24	Method for treating diabetes employing an aP2 inhibitor and combination
JP2020500838A (ja)	2020-01-16	Α−アミノ−β−カルボキシムコン酸セミアルデヒドデカルボキシラーゼの阻害剤
JP2002510623A (ja)	2002-04-09	抗糖尿病薬
US20040102524A1 (en)	2004-05-27	Method of treatment
WO2011002011A1 (ja)	2011-01-06	Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬
MXPA01002414A (en)	2001-12-04	METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION
US20040254370A1 (en)	2004-12-16	Carboxylic acid derivatives compounds and agents comprising the compounds as active ingredient
ERION	2012	QUN DANG*, PAUL D. VAN POELJE AND